Featured Research

from universities, journals, and other organizations

Study Finds Tarceva Benefits Older Lung Cancer Patients

Date:
September 19, 2005
Source:
Dana-Farber Cancer Institute
Summary:
The tyrosine kinase inhibitor erlotinib (Tarceva®) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston.

COPENHAGEN--The tyrosine kinase inhibitor erlotinib (Tarceva®)showed encouraging activity with relatively tolerable side effects inelderly, previously untreated patients with advanced non-small celllung cancer (NSCLC), reports a team led by investigators fromDana-Farber Cancer Institute in Boston.

The uncontrolled, Phase II results are sufficiently promising tomerit a Phase III trial comparing erlotinib with single-agent navelbinein this population, the researchers say. The findings will be presentedat the 15th Annual Congress of the European Respiratory Society inCopenhagen, Denmark.

"While further research is needed, our findings suggest that itmay be beneficial to use erlotinib, a relatively non-toxic targetedagent, to initially treat patients with advanced lung cancer, ratherthan use conventional chemotherapy regimens," said Dana-Farber's BruceJohnson, MD, who headed the research.

Erlotinib is designed to specifically and potently block anoveractive growth-signaling molecule (EGFR) in cancer cells. Earlierstudies have shown that erlotinib produced promising activity in NSCLCpatients for whom chemotherapy has failed. The single-center Phase 2study being reported now is the first assessment of erlotinib inpatients who have not received chemotherapy.

David M. Jackman, MD, is the first author of the abstract, and Pasi A. Janne, MD, PhD, is the senior author.

The 80 patients in the study were treated with erlotinib between2003 and 2005 at Dana-Farber. All had Stage IIIB or IV disease; halfwere male; median age was 75, and all but five were current or formersmokers.

All patients were evaluated for survival and toxicity; 69 wereevaluated for best response. Ten patients were discontinued from thestudy because of toxicity, and there was one treatment-related deathfrom pneumonitis. Rashes (74 percent of patients) and diarrhea (60percent) were the most common side effects.

There were no complete responses to the drug, but 60 percent ofthe patients experienced either a partial response or had stabledisease. Eight patients had partial responses, 33 had stable diseaseand 28 had progressive disease. The median survival was 46 weeks, andthe median duration of partial response and stable disease was 65 weeksand 24 weeks, respectively.

The researchers conclude that erlotinib "appears to berelatively well-tolerated and demonstrates encouraging activity andmedian survival" in previously untreated patients 70 years or olderwith NSCLC.

In addition to Jackman, Janne and Johnson, the study's otherauthors are Joan Lucca, RN, Michael Rabin, MD, and Arthur Skarin, MD,of Dana-Farber; and Thomas Lynch, MD, Patricia Ostler, RN, JenniferTemel, MD, and Panagiotis Fidias, MD, of the Massachusetts GeneralHospital.

###

The research was funded in part by Genentech.

Dana-Farber Cancer Institute (www.dana-farber.org)is a principal teaching affiliate of the Harvard Medical School and isamong the leading cancer research and care centers in the UnitedStates. It is a founding member of the Dana-Farber/Harvard CancerCenter (DF/HCC), designated a comprehensive cancer center by theNational Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Study Finds Tarceva Benefits Older Lung Cancer Patients." ScienceDaily. ScienceDaily, 19 September 2005. <www.sciencedaily.com/releases/2005/09/050918131511.htm>.
Dana-Farber Cancer Institute. (2005, September 19). Study Finds Tarceva Benefits Older Lung Cancer Patients. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2005/09/050918131511.htm
Dana-Farber Cancer Institute. "Study Finds Tarceva Benefits Older Lung Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2005/09/050918131511.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins